Get the Stockscreener App
1.71
0.59%
+0.01
After Hours:
1.71
Cerus Corp. stock is currently priced at $1.71, with a 24-hour trading volume of 382.20K.
It has seen a +0.59% increased in the last 24 hours and a -1.72% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.68 pivot point. If it approaches the $1.74 resistance level, significant changes may occur.
Previous Close:
$1.70
Open:
$1.72
24h Volume:
382.20K
Market Cap:
$309.99M
Revenue:
$156.37M
Net Income/Loss:
$-37.49M
P/E Ratio:
-5.8966
EPS:
-0.29
Net Cash Flow:
$-47.77M
1W Performance:
+1.79%
1M Performance:
-1.72%
6M Performance:
+31.54%
1Y Performance:
-27.23%
1D Range:
$1.665
$1.72
52W Range:
$1.205
$3.08
Cerus Corp. Stock (CERS) Company Profile
Name
Cerus Corp.
Sector
Industry
Phone
925-288-6000
Address
2550 Stanwell Drive, Concord, CA
Cerus Corp. Stock (CERS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-17-23 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Jun-16-20 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-26-20 | Initiated | BTIG Research | Buy |
| Nov-13-19 | Upgrade | BTIG Research | Neutral → Buy |
| Aug-28-19 | Initiated | Stifel | Buy |
| Aug-23-19 | Resumed | Stephens | Overweight |
| Jan-05-18 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-08-17 | Resumed | BTIG Research | Neutral |
| Jul-07-16 | Resumed | Cantor Fitzgerald | Buy |
| Dec-17-15 | Downgrade | Wedbush | Outperform → Neutral |
| May-02-14 | Reiterated | MLV & Co | Buy |
| Apr-24-13 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-15-13 | Reiterated | MLV & Co | Buy |
| Apr-17-12 | Initiated | Cantor Fitzgerald | Buy |
| Feb-29-12 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-10-11 | Reiterated | MLV & Co | Buy |
| Jun-03-11 | Initiated | Wedbush | Outperform |
| Mar-04-11 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-09-10 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-26-09 | Upgrade | Avondale | Mkt Perform → Mkt Outperform |
View All
Cerus Corp. Stock (CERS) Latest News
Perion Network Cuts Sales Outlook, Joins Range Resources And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga
Cathie Wood's Ark Invest Sells Another Tranche Of Block Shares, Even As Bitcoin Price Stages A Recovery
Benzinga
Cathie Wood's Ark Invest Sells Coinbase Shares As Bitcoin Hits Yet Another All-Time New High, Buys Stock Of This Social Media Company
Benzinga
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
Benzinga
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The Motley Fool
Cerus Corp. Stock (CERS) Financials Data
Cerus Corp. (CERS) Revenue 2024
CERS reported a revenue (TTM) of $156.37 million for the quarter ending December 31, 2023, a -3.51% decline year-over-year.
Cerus Corp. (CERS) Net Income 2024
CERS net income (TTM) was -$37.49 million for the quarter ending December 31, 2023, a +12.37% increase year-over-year.
Cerus Corp. (CERS) Cash Flow 2024
CERS recorded a free cash flow (TTM) of -$47.77 million for the quarter ending December 31, 2023, a -72.97% decrease year-over-year.
Cerus Corp. (CERS) Earnings per Share 2024
CERS earnings per share (TTM) was -$0.21 for the quarter ending December 31, 2023, a +16.00% growth year-over-year.
About Cerus Corp.
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
1.69%
0.48%
Cap:
|
Volume (24h):